会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Soluble branched triaroylbenzene-based polymer and its synthetic method
    • 可溶性支链三芳基苯基聚合物及其合成方法
    • US08143465B2
    • 2012-03-27
    • US11417290
    • 2006-05-02
    • Ben Zhong TangHongchen DongAnjun QinMatthias Haeussler
    • Ben Zhong TangHongchen DongAnjun QinMatthias Haeussler
    • C07C15/00C07C45/00B01J19/12
    • C08G61/124C08G61/00
    • The present invention relates to a novel process of preparing branched polymers by cyclotrimerization and branched organic materials containing triaroylbenzene moieties as base structural unit. The polymerization is a simple one-pot reaction, strictly regioselective and highly functionality-tolerant giving oligomeric and polymeric polymers with high degree of branching (up to 100%) in high yields (up to 99%). The polymers are processible, easily film-forming, transformable (curable) into thermosets by heat or irradiation, and readily crosslinkable by UV irradiation to give patterns with nanometer resolution. The polymers of the present invention can be blend with a variety of macromolecules for general use. The polymers can be metallified utilizing organometallic acetylene as building blocks and ceramization of the patterns of the obtained polymers afford ferromagnetic ceramic patterns with high resolution.
    • 本发明涉及通过环三聚化制备支链聚合物和含有三芳基苯部分作为基础结构单元的支链有机材料的新方法。 聚合是一种简单的一锅反应,严格地区域选择性和高度官能度的产生,具有高分支(高达100%)的高分子量聚合物(高达99%)。 聚合物是可加工的,易成膜的,通过热或照射可转化(可固化)成热固性材料,并且可以通过UV照射容易地交联,以提供纳米分辨率的图案。 本发明的聚合物可以与各种大分子共混使用。 聚合物可以使用有机金属乙炔作为结构单元进行金属化,并且所得聚合物的图案的陶瓷化提供具有高分辨率的铁磁性陶瓷图案。
    • 8. 发明申请
    • ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME
    • 腺苷A1和A3受体基因序列变异预测疾病结局和治疗结果
    • US20100047798A1
    • 2010-02-25
    • US12514031
    • 2007-11-08
    • Arthur M. FeldmanZhong Tang
    • Arthur M. FeldmanZhong Tang
    • C12Q1/68C07H21/04C07K2/00C07K16/00G06F19/00
    • C12Q1/6883C12Q2600/106C12Q2600/156C12Q2600/158
    • The present invention relates to methods for identify subjects for responsiveness to adenosine agonist treatment. Another aspect of the present invention relates to methods to predict a relative infarct size in response to ischemia reperfusion injury. In particular, the present invention relates to methods for to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences such as mutations and/or polymorphisms in the human A1 adenosine receptor (A1-AR) gene that alters the stability of the A1-AR mRNA. Other aspect of the present invention relates to methods to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences, such as mutations and/or polymorphisms in the human A3 adenosine receptor (A3-AR) gene that alters the A3-AR protein function. Other aspect of the present invention also relate to kits and assays to detect sequence differences in the human A1 adenosine receptor (A1-AR) gene and/or A3 adenosine receptor (A3-AR) gene.
    • 本发明涉及用于识别对腺苷激动剂治疗的反应性的受试者的方法。 本发明的另一方面涉及预测相对于缺血再灌注损伤的相对梗死面积的方法。 特别地,本发明涉及通过鉴定人类A1腺苷受体(A1-AR)基因中的变异和/或多态性的序列差异来鉴定对腺苷激动剂治疗和/或相对梗死面积的反应性的方法, A1-AR mRNA的稳定性。 本发明的另一方面涉及通过鉴定人类A3腺苷受体(A3-AR)基因中的序列差异(例如突变和/或多态性)来改变对腺苷激动剂治疗和/或相对梗死面积的反应性的方法, A3-AR蛋白功能。 本发明的另一方面还涉及用于检测人A1腺苷受体(A1-AR)基因和/或A3腺苷受体(A3-AR)基因中的序列差异的试剂盒和测定法。